Platform|API|Archive|Contact
Humanexa SignalsPharmaceutical Intelligence
Subscribe
Signals
Regulatory
  • FDA
  • EMA
  • MHRA
  • PMDA
  • Health Canada
Clinical
  • Phase I
  • Phase II
  • Phase III
  • Readouts
  • Enrollment Signals
Competitive
  • Pipeline Tracking
  • Company Moves
  • Asset Intelligence
  • Landscape Reports
Markets
  • Pricing
  • Access
  • Commercial
  • Launch Tracking
M&A Watch
  • Licensing
  • Acquisitions
  • Partnerships
  • Capital Raises
StrategyCatalystsPricing
Humanexa Signals

Data-driven pharmaceutical intelligence for biotech investors, pharma operators, consultants, and intelligence teams.

Powered by Humanexa

Categories

  • Regulatory
  • Clinical
  • Competitive
  • Markets
  • M&A Watch
  • Strategy
  • Catalyst Tracker

Company

  • Pricing
  • Partner with us
  • Subscribe
  • Contact
  • Privacy

Subscribe to Humanexa Signals

Weekly intelligence for pharma decision-makers.

No paywall. No spam. Unsubscribe anytime.

© 2026 Humanexa Signals. All rights reserved.

Intelligence powered by the Humanexa engine.

ClinicalOncologyBreast TumorsTrial Update

Large Study on Breast Phyllodes Tumors in China Aims to Enhance Treatment Guidelines

A multi-center, retrospective study will analyze real-world data from 3,500 patients with breast phyllodes tumors in China.

Published: June 17, 2026
Updated: June 17, 2026
Author: Humanexa Intelligence
Therapeutic area: Oncology / Breast Tumors
Company: Roche
Asset: Herceptin
Trial SummaryCLN

Phase III

Oncology / Breast Tumors

Enrollment

500

Status

Active

Sponsor

Roche

Signal Score

8.2

Signal assessment

Signal strength

high

Confidence level

moderate

Signalhigh
Confidencemoderate

Why it matters

This large-scale study on breast phyllodes tumors in China addresses a significant gap in understanding this rare tumor type within Asian populations. The findings could lead to improved treatment guidelines and personalized strategies, impacting future research and competitive positioning in oncology.

Recommended action

Humanexa recommends Monitor: Monitoring is recommended to track the study's progress and outcomes, as they may lead to important updates in treatment protocols that could affect market dynamics and clinical practices.

Analysis

Monitor the study's progress and outcomes related to local recurrence, distant metastasis, and overall survival metrics.

Related companies & assets

Companies

  • Roche →

Assets

  • Herceptin →
  • Oncology →

Sources & Humanexa intelligence

Source links

  • Breast Phyllodes Tumors: Based on 20-year Real-world Data From China ↗
  • Large Study on Breast Phyllodes Tumors in China Aims to Enhance Treatment Guidelines ↗

Related Humanexa pages

  • Large Study on Breast Phyllodes Tumors in China Aims to Enhance Treatment Guidelines →

Related signals

Trial SummaryCLN

Phase III

Infectious Disease / T Cell Therapy

Status

Active

Signal Score

8.4

Clinicalhigh signal

Study on Multivirus CTL for Viral Infections Post Allogeneic SCT Shows Promise

A study is investigating the use of banked virus-specific T cells (VSTs) to treat persistent viral infections after allogeneic stem cell transplants.

August 2, 2026Read signal →
Trial SummaryCLN

Phase II

Oncology / Neuroendocrine Carcinomas

Status

Active

Signal Score

8.4

Clinicalhigh signal

Phase II/III Trial of Atezolizumab with Chemotherapy for Advanced Neuroendocrine Carcinomas

A phase II/III trial is evaluating the efficacy of atezolizumab combined with standard chemotherapy in advanced or metastatic neuroendocrine carcinomas originating outside the lung.

August 1, 2026Read signal →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.

  1. Home
  2. /Clinical
  3. /Large Study on Breast Phyllodes Tumors in China Aims to Enhance Treatment Guidelines